PARP inhibitors for targeted treatment in ovarian cancer
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference6 articles.
1. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy;Kim;Clin Cancer Res,2015
2. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial;Swisher;Lancet Oncol,2017
3. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer;Mirza;N Engl J Med,2016
4. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer;Ledermann;N Engl J Med,2012
5. Pujade-Lauraine E, Ledermann J, Penson R, et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Society of Gynecologic Oncology Annual Meeting on Women's Cancer, National Harbor, MD, USA; March 12–15, 2017.
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Parthanatos: Mechanisms, modulation, and therapeutic prospects in neurodegenerative disease and stroke;Biochemical Pharmacology;2024-03
2. Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis;International Journal of Biological Sciences;2024
3. Systemische Therapie der epithelialen serösen Ovarialkarzinome;Deutsche Zeitschrift für Onkologie;2023-12
4. Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres;BMJ Open;2023-11
5. Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies;Molecular Therapy - Oncolytics;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3